DELTICOM-AG/YOURTYRES
13.10.2016 12:09:02 CEST | Business Wire | Press release
They’re technological milestones with cult status and are now in high demand: modern classics. Lovers of the Saab 900, the Ford Granada, the Audi 80 and co. place great importance on maintaining their vehicles as true to the original condition as possible. This applies in particular to parts that are prone to wear, such as tyres. Sooner or later they have to be replaced, as even with low mileage they age, harden and eventually crack. “An opportunity for tyre dealers and workshops: even businesses that don’t specialise in classic cars or modern classics can capture the cult vehicle fan target group”, explains Andreas Faulstich, Head of B2B at Delticom, Europe’s largest online tyre retailer, and parent company to the online shop for dealers,Yourtyres.co.uk . “It’s impossible for one retailer to stock absolutely every model and dimension of tyre for historical cars. This is where Yourtyres.co.uk’s retail partnership model comes into play, effectively binding online and offline trade together in a way that is profitable for both sides.”
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161013005602/en/
Yourtyres.co.uk offers a wide range of historical tyre models and dimensions that today are produced to meet current standards by many well-known manufacturers, for example the “Sprint Classic” by Vredestein, or Maxxi’s “MA 1”. Exclusive to Delticom’s dealer shop, commercial customers can get their hands on the “Retro Classic 001” by Retro, a classic car tyre offering a great price-performance ratio, produced in-house by Nankang and also available as a whitewall tyre.
Searching for the perfect tyre is quick and easy. Prospective buyers can search by tyre dimension or vehicle model. Thanks to its own stock holding and consequent high availability, commercial customers also benefit from one of Yourtyres.co.uk ’s greatest strengths: its flexibility. Delivery times are short, and shipping is free from the very first tyre. If you need advice, you can contact Delticom’s experienced B2B Services team via email or by phone. Consultants are available from 7am to 10pm Monday to Friday, above and beyond normal business hours. Favourable purchase prices also allow partners of Delticom B2B and Yourtyres.co.uk to achieve attractive margins.
“We want to enable dealers and workshops to increase their end-user reach. Distributing historical tyre models is a great way to do this. Another way to increase your reach even further is to register as a fitting partner for Yourtyres.co.uk free of charge. This provides businesses with the potential to benefit from each and every online purchase in one of our end-customer shops”, expands Faulstich. “In addition to tyre fitting, further services can be connected to workshops or retail outlets, enabling an expansion of the business.”
About Yourtyres.co.uk
Yourtyres.co.uk de is the exclusive online store from Delticom AG for workshops, retailers, wholesalers, tyre fitters/service stations and car accessories. With over 15 years’ expertise in the online tyre business, the Yourtyres.co.uk specialist B2B team offers its clients a spectacular range of car and motorbike tyres of all brands and dimensions for all types of vehicles, tyres for light trucks, trucks and buses, custom tyres, complete wheel sets, car spare parts and accessories, engine oil and batteries. In addition to favourable purchasing conditions, retail clients benefit from the online shop’s time-saving tyre search function, high availability, reliable delivery thanks to in-house warehouses, as well as a simple registration process with no hidden costs - from the very first tyre.
Online shop for dealers and workshops in the UK: www.yourtyres.co.uk and 24 further countries.
Information about the company : www.delti.com
Tyre tests : www.tyretest.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161013005602/en/
Contact:
insignis Agentur für
Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom